Tiger Brokers

3D Medicines Recovers HK$7.98 Million in Arbitration with SELLAS; 3D189 Trial Reaches 78 of 80 Target Events

Bulletin Express
Aug 18

3D Medicines Inc. (3D Medicines) announced the successful enforcement of an arbitral award against SELLAS Life Sciences Group, Inc., receiving full payment of HK$7.98 million in costs. The settlement concludes a licence-related dispute that was dismissed in its entirety by a sole arbitrator, who ordered SELLAS to bear 3D Medicines’ arbitration expenses.

The company confirmed that the ruling is final and binding and does not affect the validity or ongoing execution of the existing licence agreement between the two parties.

Operationally, 3D Medicines reported that the global multi-regional clinical trial (MRCT) of its oncology candidate 3D189 has recorded 78 efficacy events, approaching the predefined endpoint of 80 events.

Shareholders and potential investors are advised to remain prudent when dealing in the company’s securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10